What Is Tertiary Hyperparathyroidism?

Tertiary hyperparathyroidism is a condition in which the parathyroid glands, after being overstimulated for months or years by chronic kidney disease, begin secreting parathyroid hormone (PTH) on their own regardless of whether the original trigger has been corrected. Unlike secondary hyperparathyroidism, where PTH rises as an appropriate response to low calcium, tertiary hyperparathyroidism involves glands that have grown and changed enough to operate autonomously, pushing both PTH and blood calcium above normal levels.¹ It most commonly surfaces after a successful kidney transplant restores normal kidney function but the parathyroid glands fail to dial back, though it can also develop in people still on dialysis or, rarely, from other conditions entirely.

How Parathyroid Glands Go Rogue

In a healthy body, the four small parathyroid glands behind the thyroid sense blood calcium levels and release PTH to raise calcium when it drops too low. Chronic kidney disease disrupts this feedback loop in several ways: failing kidneys cannot activate enough vitamin D, phosphorus builds up, and calcium falls. The parathyroid glands respond by producing more PTH and physically growing larger. Over time, this constant overdrive causes structural changes in the glands themselves. Cells that were once responsive to calcium signals become hyperplastic or even develop into small benign tumors (adenomas). At a certain point, even if kidney function is restored through transplantation, these enlarged glands keep churning out PTH because they have, in effect, lost the ability to recognize that calcium is already adequate.

Research into the molecular side of this process points to changes in calcium-sensing receptors and a signaling molecule called Klotho. A study of parathyroid tissue from kidney transplant recipients found that Klotho expression in the parathyroid glands was significantly reduced compared to healthy controls and did not fully recover after transplantation.² Without adequate Klotho, the glands are less responsive to the signals that would normally tell them to ease off PTH production. This incomplete molecular recovery helps explain why some transplant recipients develop tertiary hyperparathyroidism while others see their PTH normalize within months.

Who Develops It and When

The vast majority of tertiary hyperparathyroidism cases occur after kidney transplantation. Among transplant recipients, roughly two-thirds still have elevated PTH a year after surgery.³ Not all of these cases qualify as full-blown tertiary disease with autonomous hypercalcemia, but the number highlights how common persistent overactivity of the parathyroid glands is in this population.

Several factors raise the odds. A large study of kidney transplant recipients identified older age at transplantation, longer time spent on dialysis before the transplant, higher pretransplant calcium and PTH levels, and a history of acute rejection as independent risk factors.⁴ The dialysis duration stands out as particularly intuitive: the longer the glands are forced to work overtime, the more entrenched the overgrowth becomes. An older study looking specifically at post-transplant hypercalcemia found that the problem appeared within the first year in about 90% of those who developed it, and it too was linked to a longer pre-transplant dialysis history.⁵

In a study of hypercalcemic transplant recipients, about two-thirds of cases were classified as persistent hyperparathyroidism rather than a transient bump in calcium. The persistent group had higher peak calcium levels (a median of roughly 12.2 mg/dL versus 11.6 mg/dL in the transient group) and a far longer duration of elevated calcium, with a median around 25 months compared to 12 months.⁶ So there is a real distinction between post-transplant calcium that bounces up briefly and then settles, and calcium that stays elevated because the parathyroid glands have fundamentally changed.

What Tertiary Hyperparathyroidism Does to the Body

Chronically elevated PTH paired with high calcium is not a benign combination. The effects ripple across multiple organ systems, and for transplant recipients the stakes are especially high because the transplanted kidney itself is at risk.

Bones and Fractures

PTH at normal levels actually helps maintain bone, but sustained excess PTH accelerates bone turnover in a way that weakens the skeleton. In male kidney transplant recipients, PTH was the strongest independent predictor of bone mineral density at the wrist and was also linked to lower density at the hip.⁷ This bone loss translates directly into fractures. A longitudinal study found that transplant recipients with persistent hyperparathyroidism at one year post-transplant had roughly three times the fracture risk of those whose PTH had normalized.⁸ Another study following patients for five years after transplant found that a PTH level above 130 ng/L at three months was associated with a more than sevenfold increase in fracture risk.⁹

The Transplanted Kidney

High calcium is directly harmful to the kidney graft. In a large cohort of over 1,200 transplant recipients, those with hypercalcemic hyperparathyroidism had a ten-year graft survival rate of only about 80%, compared with much higher rates in patients whose calcium was normal or who received treatment. Hypercalcemia in the first year after transplant was also linked to progression of scarring (fibrosis) within the graft.¹⁰ Reassuringly, the same study found that patients who received treatment for their hyperparathyroidism did not face that increased risk. A separate analysis confirmed this from a different angle: transplant recipients who had their hyperparathyroidism treated, whether with surgery or medication, had substantially lower rates of graft failure compared with untreated patients.¹¹

Cardiovascular and Soft-Tissue Effects

Beyond bones and kidneys, chronically elevated PTH and the associated mineral imbalances contribute to vascular calcification, where calcium deposits accumulate in blood vessel walls. This is one of the most serious metabolic consequences of hyperparathyroidism in kidney disease.¹² In severe cases, particularly in end-stage kidney disease, tertiary hyperparathyroidism can drive autonomous PTH secretion that leads to soft-tissue calcification, blood vessel disease, and abnormal bone remodeling.¹³

An especially feared complication is calciphylaxis, in which calcium deposits clog small and medium-sized arteries in the skin and underlying tissue. The resulting loss of blood supply causes painful, discolored skin lesions that can progress to tissue death.¹⁴ Calciphylaxis is rare but carries a high mortality rate, making it one of the strongest arguments for not ignoring persistently elevated calcium and PTH.

Diagnosing and Localizing the Problem

The biochemical diagnosis is straightforward: elevated PTH together with elevated calcium in someone with a history of chronic kidney disease, particularly after a transplant that should have removed the original stimulus for high PTH. The tricky part is not recognizing that tertiary hyperparathyroidism exists but pinpointing which glands are overactive and how large they have become, especially when surgery is being considered.

Traditional imaging for parathyroid disease includes ultrasound and sestamibi scintigraphy (a nuclear scan using a radioactive tracer). These work reasonably well for the single enlarged gland typical of primary hyperparathyroidism, but in tertiary disease all four glands are often enlarged, making precise localization harder. Newer imaging using a PET/CT scan with a fluorocholine tracer has shown dramatically better results. One study found that fluorocholine PET/CT correctly identified overactive glands in about 72% of cases on a per-gland basis, compared with only 25% for ultrasound and 35% for sestamibi scintigraphy. In patients with tertiary disease specifically, the sensitivity jumped to 88%.¹⁵ A separate study confirmed the advantage, reporting fluorocholine PET/CT sensitivity of 86% versus 55% for sestamibi and 62% for ultrasound, with comparable specificity across all three.¹⁶

This matters because surgeons operate more confidently and efficiently when they know exactly which glands are problematic before making an incision. In tertiary disease, where the plan is usually to remove most or all of the glands, good preoperative imaging helps identify ectopic (unusually located) glands and ensures nothing gets missed.

Medication as a First-Line Approach

Cinacalcet is the main medication used to manage tertiary hyperparathyroidism. It works by making the calcium-sensing receptors on the parathyroid glands more sensitive to calcium, effectively tricking them into behaving as though calcium levels are higher than they are, which reduces PTH output. In transplant recipients with persistent hyperparathyroidism, cinacalcet consistently brings calcium levels down. An early study showed calcium dropping from an average of about 11 mg/dL to around 9.7 mg/dL within two months, with PTH also falling significantly.¹⁷ A meta-analysis of multiple studies confirmed that cinacalcet reduced calcium by about 1.1 mg/dL and PTH by about 102 pg/mL on average, with no significant change in kidney function.¹⁸

The catch is that cinacalcet does not shrink the parathyroid glands or reverse their autonomous behavior. It controls symptoms for as long as you take it, and stopping the drug typically causes calcium and PTH to climb back up. Side effects include gastrointestinal issues like nausea and vomiting, which caused some patients in trials to stop the medication, and occasionally calcium can drop too low. Because cinacalcet must be taken indefinitely, cost becomes a real consideration, which leads directly to one of the more practical questions patients and clinicians face.

When Surgery Makes More Sense

Parathyroidectomy, the surgical removal of some or all of the parathyroid glands, is the definitive treatment for tertiary hyperparathyroidism. It directly addresses the root cause: glands that have grown too large and too autonomous to respond to normal feedback. Guidelines at specialized centers typically recommend surgery for patients with marked hypercalcemia (calcium above 12 mg/dL), persistent hypercalcemia above 11 mg/dL accompanied by symptoms or complications like kidney stones, graft dysfunction, worsening bone loss, or fatigue, and for cases where hypercalcemia above 11 mg/dL persists beyond one year after transplant.¹⁹

Timing matters more than many clinicians appreciate. A study comparing different windows found that parathyroidectomy performed within the first year after transplant was associated with a 57% lower risk of kidney stones and patients were twice as likely to maintain normal kidney function compared with those who had surgery one to three years out. Going even earlier, within six months of transplant, lowered the risk of persistent hypercalcemia and kidney stones by about 62% compared with surgery between six months and one year.²⁰ The tension is that operating too soon risks catching patients whose hyperparathyroidism might have resolved on its own, while waiting too long exposes the graft to cumulative damage from high calcium.

From a cost standpoint, surgery is hard to argue against for patients who will otherwise need cinacalcet indefinitely. A cost-effectiveness analysis found that parathyroidectomy cost roughly $1,300 versus over $7,100 for cinacalcet therapy, with surgery also producing more quality-adjusted life years. Parathyroidectomy became the more cost-effective option once cinacalcet treatment would last more than about nine months.²¹ A randomized trial reached a similar conclusion, finding surgery more cost-effective than cinacalcet once treatment duration reached about 14 months.²²

Subtotal Versus Total Parathyroidectomy

When surgery is chosen, there are two main approaches. A subtotal parathyroidectomy removes three and a half of the four glands, leaving a small remnant in the neck to produce enough PTH to keep calcium from dropping too low. A total parathyroidectomy removes all four glands, with a small piece of one reimplanted into the forearm or another muscle, where it can be easily accessed if it later causes problems. Both procedures cure the hypercalcemia in the vast majority of cases. A meta-analysis found cure rates between 98% and 100% with no meaningful difference between the two techniques.²³

Where the techniques do differ is in the risk of leaving the patient with too little PTH afterward. One study comparing the two approaches in transplant recipients found that total parathyroidectomy with autotransplantation led to hypoparathyroidism (either temporary or permanent) at roughly double the rate of subtotal parathyroidectomy. About 21% of patients who had total removal developed permanent hypoparathyroidism versus about 10% in the subtotal group. Recurrence and persistence rates, however, were statistically similar between the two.²⁴ This trade-off means surgeons often favor the subtotal approach for transplant recipients, accepting a small theoretical risk of recurrence in exchange for a much lower chance of leaving the patient permanently dependent on calcium and vitamin D supplements.

Hungry Bone Syndrome After Surgery

One complication specific to parathyroidectomy in patients with long-standing hyperparathyroidism is hungry bone syndrome. When PTH drops abruptly after surgery, bones that have been losing calcium for months or years suddenly begin reclaiming it from the bloodstream. Calcium levels can plummet rapidly, sometimes to dangerous levels requiring intravenous calcium infusion in the hospital. A study of patients undergoing parathyroidectomy for renal hyperparathyroidism found that nearly half developed hungry bone syndrome. Those who did had significantly higher preoperative PTH, phosphorus, and alkaline phosphatase, and lower preoperative calcium. A scoring system using just two variables, alkaline phosphatase above 150 U/L and PTH above 1,000 pg/mL, predicted the syndrome with about 97% accuracy.²⁵ Knowing who is at highest risk allows surgical teams to prepare with aggressive calcium supplementation in the immediate postoperative period.

Tertiary Hyperparathyroidism Without Kidney Disease

While the post-transplant setting dominates the clinical conversation, tertiary hyperparathyroidism can develop from any condition that drives secondary hyperparathyroidism long enough. Any prolonged stimulus that keeps the parathyroid glands chronically overactive can eventually push them toward autonomous function. A case report documented tertiary hyperparathyroidism in a patient with X-linked hypophosphatemic rickets, a genetic condition causing phosphate wasting and low blood phosphorus, who had been treated for years with calcitriol and high-dose oral phosphate. The sustained phosphate supplementation chronically stimulated PTH production, and over time the glands became autonomous.²⁶ Similarly, five patients with pseudohypoparathyroidism type 1B, a condition involving resistance to PTH action, developed tertiary disease decades after their initial diagnosis, requiring either surgery or cinacalcet to control the resulting hypercalcemia.²⁷

These non-renal cases are rare but worth knowing about, particularly for patients on long-term treatment for inherited mineral disorders. They reinforce the core principle: any condition that chronically overstimulates the parathyroid glands carries the potential for those glands to eventually escape normal control. The treatment approach, whether medication or surgery, follows the same logic as in the post-transplant setting, tailored to the severity of the hypercalcemia and the patient’s overall clinical picture.